MiR-424-5p has been shown to reduce cell viability by modulating the PTEN/PI3K/AKT/mTOR pathway in breast-cancer cells [34], the MAPK pathway in ischemic stroke [35], and the Hippo-signaling pathway in thyroid cancer [36]. This evidence concerns the gene AKT1 and thyroid cancer.